LZTR1 Inhibitors
The inhibitors listed above target various components of the RAS/MAPK signaling pathway and other related cellular processes, which could indirectly influence LZTR1 activity. Given LZTR1's involvement in tumor suppression and cell signaling, modulation of these pathways is relevant for understanding its function and potential regulation. MEK, ERK, and JNK inhibitors can impact the RAS/MAPK signaling pathway at different points, potentially affecting processes regulated by LZTR1.
Sorafenib and Selumetinib, as well as other kinase inhibitors like SP600125 and PD98059, can modulate cellular signaling pathways relevant to LZTR1's function. mTOR and PI3K inhibitors, such as Rapamycin and Wortmannin, may influence cell growth and survival pathways, potentially impacting LZTR1-associated mechanisms. B-Raf inhibitors and EGFR inhibitors (Cetuximab, Gefitinib) target upstream components of the RAS/MAPK pathway, potentially influencing LZTR1's role in cellular signaling and tumorigenesis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
MEK inhibitors can affect the RAS/MAPK signaling pathway, potentially influencing processes regulated by LZTR1. | ||||||
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $370.00 | 5 | |
ERK inhibitors target downstream components of the RAS/MAPK pathway, potentially impacting LZTR1-associated signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib, a multi-kinase inhibitor, targets RAS/MAPK pathway among others, potentially affecting LZTR1-related processes. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib, another MEK inhibitor, might influence pathways involving LZTR1 through its action on the RAS/MAPK signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that may affect downstream signaling pathways relevant to LZTR1. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, an inhibitor of MEK, could indirectly impact LZTR1 function by modulating the RAS/MAPK pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, can affect cell growth and proliferation, potentially impacting LZTR1-related pathways. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, might impact pathways associated with LZTR1, especially in the context of cell proliferation and survival. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
B-Raf inhibitors affect the RAS/MAPK signaling cascade, potentially impacting LZTR1-regulated pathways. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib, another EGFR inhibitor, can affect cell signaling pathways relevant to LZTR1's role in tumorigenesis. | ||||||